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Extracorporeal membrane oxygenation (ECMO) is increasingly used in cases of respiratory or circula-tory failure refractory to conventional treatment. 
Neurologic injury, including cerebrovascular hemorrhage, 
ischemia, and infarction, is a complication of ECMO linked 
to increased morbidity and mortality. Most data on neu-
rologic injury derive from patients undergoing ECMO for 
cardiac indications or after cardiopulmonary resuscita-
tion1 with additional smaller data sets in patients treated 
with either venovenous (v-v) or venoarterial (v-a) ECMO 
for other cardiac and respiratory indications.2,3 As a result, 
the reported rate of neurologic injury ranges widely from 
11% to 50%. In a 2009 patient cohort receiving mainly v-v 
ECMO for H1N1 influenza–associated acute respiratory 
distress syndrome (ARDS), the rate of intracerebral hemor-
rhage (ICH) was 9%4 and 11% in patients undergoing v-v 
ECMO for other indications.5 The aim of this single-center 
report was to describe the incidence of neurologic injury in 
patients undergoing ECMO for severe ARDS and briefly 
review existing literature.
METHODS
Ethical Approval and Consent to Participate
This retrospective analysis was approved by the Cantonal 
Ethikkommission Zurich (KEK-ZH-Nr. 2014-0318), which 
waived the need for informed consent.
Study Design and Objectives
All patients undergoing ECMO therapy for ARDS at the 
University Hospital of Zurich between January 1, 2008, 
and December 31, 2013, were included. Local guidelines 
were used as criteria for initiating ECMO as previously 
described.6 ECMO was performed primarily in the v-v con-
figuration. V-A cannulation was chosen in selected patients 
when v-v ECMO was anticipated to be insufficient, as in 
cases of moderate to severe heart failure, severe hypoxemia, 
hemodynamic instability, or pulmonary hypertension.
While on ECMO, the hematocrit was maintained 
above 28% and platelet count was kept over 50,000/µL. 
Unfractionated heparin was administered to target an anti-
factor Xa activity of 0.2–0.3 IU/mL or activated clotting time 
(ACT) of 150–180 seconds for all ECMO.
Data Collection
Baseline values were collected on all patients. During ECMO 
therapy, the lowest thrombocyte count, lowest hematocrit, 
and highest antifactor Xa activity and ACT value were 
recorded, as was survival 6 months after ECMO initiation. 
Patient charts were reviewed for clinical evidence of neuro-
logic dysfunction during ECMO treatment, defined as sei-
zures, loss of consciousness, and loss of brainstem reflexes 
or new-onset anisocoria. All cerebral imaging studies were 
reviewed by S.K. and U.S.
In accordance with Swiss law, autopsies were only per-
formed when the next of kin rendered approval. Available 
autopsy records and slides were reviewed by E.J.R. If the 
macroscopic autopsy examination showed only evidence 
of diffuse hypoxic-ischemic changes, a follow-up histologic 
examination was not routinely performed. The cerebral 
imaging or autopsy findings were classified as either prob-
ably related to or unlikely due to ECMO therapy by U.S. 
and E.J.R., who were blinded to each other’s assessment. 
Because no known pathognomonic morphologic or imag-
ing findings for ECMO-associated neurologic injury exist, 
the classification was based on the features of the acute ill-
ness, localization, and the neuropathologic findings. More 
This retrospective single-center study investigated the incidence of neurologic injury as deter-
mined by autopsy or cerebral imaging in 74 patients undergoing extracorporeal membrane oxy-
genation (ECMO) for acute respiratory distress syndrome. Seventy-three percent of patients 
were treated with venovenous and 27% with venoarterial ECMO. ECMO-associated intracerebral 
hemorrhage was diagnosed in 10.8% of patients. There were no cases of ischemic stroke. 
Clinical characteristics did not differ between patients with and without neurologic injury. Six-
month survival was 13% (Wilson confidence interval, 2%–47%) in patients with severe intra-
cerebral hemorrhage compared to an overall survival rate of 57% (Wilson confidence interval, 
45%–67%).  (Anesth Analg 2017;125:1544–8)
Neurologic Injury With Severe Adult Respiratory 
Distress Syndrome in Patients Undergoing 
Extracorporeal Membrane Oxygenation: A Single-Center 
Retrospective Analysis
Stephanie Klinzing, MD,* Urs Wenger, MD,† Federica Stretti, MD,*‡ Peter Steiger, MD,*  
Elisabeth J. Rushing, MD,§ Urs Schwarz, MD,‖ and Marco Maggiorini, MD†
From the *Surgical Intensive Care Unit and †Medical Intensive Care Unit, 
University Hospital of Zurich, Zurich, Switzerland; ‡Dipartimento di 
Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi 
di Milano, Milano, Italy; and Departments of §Neuropathology and ‖Neurology, University Hospital of Zurich, Zurich, Switzerland.
Accepted for publication July 13, 2017.
Funding: None.
The authors declare no conflicts of interest.
Reprints will not be available from the authors.
Address correspondence to Stephanie Klinzing, MD, Surgical Intensive Care 
Unit, University Hospital of Zurich, Raemistrasse 100, CH-8091 Zurich, 
 Switzerland. Address e-mail to Stephanie.klinzing@usz.ch.
Copyright © 2017 International Anesthesia Research Society
BRIEF REPORTE
Copyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
Neurologic Injury in ARDS Patients Undergoing ECMO
November 2017 • Volume 125 • Number 5 www.anesthesia-analgesia.org 1545
specifically, the presence of hemorrhagic and/or ischemic 
lesions not attributable to the underlying disease was con-
sidered related to ECMO therapy.
Statistical Analysis
The primary outcome of the study was the incidence of neu-
rologic injury on ECMO, while survival, baseline values, 
intensive care unit, and ECMO characteristics were second-
ary outcome parameters. Continuous variables of baseline-, 
intensive care unit–, and ECMO-specific parameters were 
compared between patients with and without neurologic 
injury using the Mann-Whitney U test. Categorical vari-
ables were compared using Pearson χ2 test or Fisher exact 
test, as appropriate. All P values were 2 sided and consid-
ered statistically significant if P ≤ .05.
Due to the retrospective nature of the study, the number 
of patients available was given. Assuming an overall sur-
vival of 62%, a survival of injured patients of 20%, and a 
proportion of injured patients of 11%, the survival of non-
injured patients would be 67%. Based on 74 patients, and a 
significance level of 5%, the Fisher exact test was calculated 
to have a power of 65%.
Statistical analysis was performed using IBM SPSS 
Statistics version 22 (IBM Corp, Armonk, NY).
RESULTS
During the study period of 6 years, a total of 309 ECMO 
runs were performed at our institution. Of these, 74 patients 
suffering from severe ARDS received ECMO therapy. Forty-
two patients (57%) survived to 6 months after ECMO initia-
tion (Wilson confidence interval, 45%–67%).
Cerebral imaging was performed in 20 patients. Due 
to unsatisfactory quality, 1 imaging study was not eligible 
for investigational purposes. Nineteen patients underwent 
computed tomography evaluation, and 1 patient under-
went magnetic resonance tomography. An autopsy was 
performed in 18 patients. In 1 patient, the autopsy did not 
include the brain.
Cerebral imaging and/or autopsy was thus performed 
in 23 of 32 nonsurvivors (72%), while cerebral imaging was 
performed in 8 of 42 survivors (19%).
Evidence of presumed ECMO-associated neurologic 
injury was diagnosed by cerebral imaging and/or autopsy 
in 8 patients (10.8%). In all cases, ICH with variable local-
ization and dimensions were diagnosed (Table and Figure). 
There were no cases of ischemic stroke.
In 3 patients, neurologic injury was assessed as not being 
associated with ECMO therapy. Two patients with sepsis 
had large intraparenchymal hemorrhagic lesions, which 
were considered likely due to septic-embolic origin. A 
single patient diagnosed with posterior reversible leukoen-
cephalopathy syndrome in the clinical setting of preeclamp-
sia had multiple, bihemispheric ischemic cerebral infarcts 
with hemorrhagic transformation.
Patients with and without neurologic injury did not 
differ in baseline characteristics and coagulation param-
eters. Patients with and without neurologic injury were 
comparable with respect to age (median, 45 [interquartile 
range {IQR}, 29–60] vs 49 [36–58]; P = .8), sex (n = 6 [75%] 
vs 36 [55%]; P = .5), and Simplified Acute Physiology Score 
(median, 47 [IQR, 37–55] vs 52 [34–64]; P = .5). No differ-
ence between groups in hematologic parameters (minimal 
thrombocyte count: median, 68 G/L [IQR, 36–134] vs 49 
G/L [25–102]; P = .5 and minimal hematocrit: median, 22% 
[IQR, 21–27] vs 21% [19–24]; P = .6) and anticoagulation val-
ues (maximal antifactor Xa activity of unfractionated hep-
arin: median, 0.72 IU/mL [IQR, 0.38–0.76] vs 0.64 IU/mL 
[0.42–1.0]; P = .7 and maximal ACT: median, 218 seconds 
[192–239] vs 225 seconds [207–264]; P = .2) were observed.
In patients with neurologic injury, 1 patient (13%) 
received v-a cannulation compared to 19 patients (29%) 
without neurologic injury. The rate of neurologic injury did 
not differ between v-a and v-v cannulation mode (P = .4, 
Fisher exact test).
Seven of 8 patients with ECMO-associated neurologic 
injury died, yielding a survival rate of 13%. Therapy was 
withdrawn in 5 patients due to severe neurologic injury and 
complete dependence on ECMO support. Two patients died 
due to complications: hemorrhagic shock after accidental 
dislocation of the ECMO cannula and circulatory failure 
due to pericardial tamponade.
The diagnosis of ECMO-associated neurologic injury 
was made at a median of 6 days (IQR, 4–23 days) after 
ECMO initiation. Patients with ECMO-associated neuro-
logic injury died at a median of 14 days (IQR, 6–31 days) 
after ECMO initiation.
DISCUSSION
In our cohort of 74 patients requiring ECMO for ARDS, 
ECMO-associated intracranial hemorrhage was diagnosed 
in 10.8% of patients with a 6-month survival of 13% (Wilson 
confidence interval, 2%–47%) compared to 57% overall 
(Wilson confidence interval, 45%–67%). Although direct 
comparison of our results with those found in other studies 
is difficult due to diverse study populations, methods, and 
the definition of neurologic injury, our data are consistent 
with previously reported incidences ranging from 3% to 
19%.2,4,5,7–9 We were unable to identify a precise trigger for 
this devastating event in our cohort. Logistical challenges 
that precluded neuroimaging studies in all ECMO patients 
may have resulted in an underestimation of the true inci-
dence of neurologic injury in our study. In contrast to the 2% 
reported by Luyt et al,5 ischemic stroke was not diagnosed 
in our study population.
The impact of ICH on patient outcome in our report 
is also consistent with published mortality rates of 60%–
92%.2,7,9 The principal finding in our study on cerebral imag-
ing and autopsy was major ICH with fatal outcome, while 
small ICH was diagnosed only in a minority of patients. 
This observation emphasizes the high probability for under-
diagnosis of neurologic injury in minor events. Hematomas 
diagnosed at autopsy were smaller than the large space-
occupying, intraparenchymal hematomas seen in patients 
where therapy was withdrawn. As reported by Risnes et al,3 
this observation suggests that the true incidence of neuro-
logic injury was higher in both survivors and nonsurvivors. 
It is possible that impaired coagulation gradually increases 
hemorrhage in patients undergoing ECMO therapy with 
anticoagulation, possibly representing a plausible explana-
tion for the late onset of clinical signs.
Copyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
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Regardless of the extent of hemorrhage, the treatment 
of ICH under ECMO support is especially challenging. 
Ongoing anticoagulation may worsen hemorrhage, while 
discontinuation may trigger thrombotic events. The surgical 
treatment of ICH remains controversial without proven 
benefit for patients under mechanical support in a 2014 case 
series.10 However, the study largely involved patients with 
left ventricular assist devices (92%) and not ECMO (8%).10
Figure. Male patient, 66 years old, with bilateral, primary viral pneumonia, who developed ARDS, which was treated with a v-v ECMO 3 days 
after admission to the ICU. A, Native cerebral CT scans at various axial (upper panel) and corresponding (white arrows in upper panel) coronal 
(lower panel) sections 9 days after ECMO installation showing multiple, massive intraparenchymal and subarachnoid hemorrhages (stars at 
exemplary locations). B, Coronal section of postmortem examination of the brain 30 days after admission revealing intracranial and subarach-
noid hemorrhage accompanied by diffuse hypoxic-ischemic encephalopathy. C, Histologic preparations show “red neurons” (arrows) in the 
deeper layers of the cerebral cortex as evidence of acute neuronal injury. ARDS indicates acute respiratory distress syndrome; CT, computed 
tomography; ICU, intensive care unit; v-v ECMO, venovenous extracorporeal membrane oxygenation.
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Changes in coagulation and excessive anticoagulation 
are potential risk factors for ICH in ARDS patients treated 
on ECMO. To date, no widely accepted protocol exists 
for determining the optimal degree of anticoagulation 
with existing approaches to anticoagulation differ widely 
between ECMO centers.8
Although the precise onset of intracranial bleeding was 
unclear in our patients, we found no difference in anticoag-
ulation or platelet counts between patients with or without 
neurologic injury. Our patient population had no evidence 
of vascular malformations or pathology as a potential 
risk factor for ICH. Bleeding was mainly localized to the 
supratentorial compartment, not clearly corresponding to 
a specific vascular territory or cannulation method. Data 
regarding this issue are sparse and inconsistent, with Risnes 
et al3 reporting a higher frequency of late cerebral sequelae 
in v-a–cannulated patients. Intraparenchymal hemorrhage 
occurred spontaneously or as a secondary event in ischemic 
areas of the brain.
In conclusion, our report demonstrates that severe ICH 
is a devastating event linked to high mortality in patients 
undergoing ECMO for severe ARDS. To reduce the inci-
dence of ICH in patients undergoing ECMO, more studies 
are needed to better define risk factors and the causes of 
ECMO-associated ICH, as well as to identify monitoring 
strategies to facilitate early diagnosis and optimal antico-
agulation. E
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